Ventures Vii L Pavalon Vent... Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ventures Vent ANAB stock SEC Form 4 insiders trading

Ventures has made over 1 trades of the AnaptysBio Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Ventures sold 37,040 units of ANAB stock worth $901,924 on 26 July 2017.

The largest trade Ventures's ever made was selling 37,040 units of AnaptysBio Inc stock on 26 July 2017 worth over $901,924. On average, Ventures trades about 37,040 units every 0 days since 2017.

You can see the complete history of Ventures Vent stock trades at the bottom of the page.

Insiders trading at AnaptysBio Inc

Over the last 8 years, insiders at AnaptysBio Inc have traded over $37,024,151 worth of AnaptysBio Inc stock and bought 5,919,575 units worth $115,520,117 . The most active insiders traders include Holdings A/S Novo, Capital, Llc Eco R1 a James N Topper. On average, AnaptysBio Inc executives and independent directors trade stock every 40 days with the average trade being worth of $4,143,306. The most recent stock trade was executed by Paul F. Lizzul on 14 August 2024, trading 2,000 units of ANAB stock currently worth $37,000.

What does AnaptysBio Inc do?

founded in 2005, anaptysbio, inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (shm) for antibody discovery and optimization. anaptysbio is building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. anaptysbio’s proprietary shm-xel platform, which couples fully human antibody libraries with in vitro somatic hypermutation (shm) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. by harnessing the natural mechanism of antibody maturation under controlled conditions, shm-xel allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. the c

Complete history of Ventures Vent stock trades at AnaptysBio Inc

AnaptysBio Inc executives and stock owners

AnaptysBio Inc executives and other stock owners filed with the SEC include:

• Hamza Suria,
  President, Chief Executive Officer, Director
• Eric Loumeau,
  Chief Operating Officer, General Counsel
• Hamza Suria,
  Pres, CEO & Director
• Dennis M. Mulroy,
  Chief Financial Officer
• Dr. Paul F. Lizzul,
  Chief Medical Officer
• James Topper,
  Independent Chairman of the Board
• Dennis Fenton,
  Independent Director
• Hollings Renton,
  Lead Independent Director
• J. Anthony Ware,
  Independent Director
• John Schmid,
  Independent Director
• Laura Hamill,
  Independent Director
• Paul Lizzul,
  Chief Medical Officer
• Dennis Mulroy,
  Chief Financial Officer
• Eric J. Loumeau,
  COO & Gen. Counsel
• David McKeon,
  VP & Controller
• Dr. Margaret Marino,
  Sr. VP of Project Management
• Beth Mueller,
  Sr. VP of HR
• Nicholas Lydon,
  Director
• Carol Giltner Gallagher,
  Director
• Matthew Moyle,
  Chief Scientific Officer
• James A Schoeneck,
  Director
• Dominic Piscitelli,
  Chief Financial Officer
• Marco Londei,
  Chief Medical Officer
• Healthcare Vii, L.P.Frazier...,
  
• Healthcare V, Lpfhm V, Lpfh...,
  
• Holdings A/S Novo,
  10% owner
• Ventures Vii L Pavalon Vent...,
  
• John A Orwin,
  
• Magda Marquet,
  
• Rita Jain,
  
• Capital, Llcnodelman Oleg E...,
  
• Capital, Llc Eco R1,
  10% owner
• Daniel Faga,
  CEO